The deal size was increased to $100M from $75M and priced at midpoint of $4.75-$5.25 range. JPMorgan and Guggenheim are acting as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics $75M Spot Secondary price range $4.75-$5.25
- Larimar Therapeutics price target raised to $14 from $12 at Citi
- Midday Fly By: Home Depot reports Q4 beat, AMD and Meta expand partnership
- Larimar Therapeutics announces FDA granted BTD to nomlabofusp
- FDA Grants Breakthrough Therapy Status to Larimar’s Nomlabofusp